Skip to main content
Erschienen in: Acta Neurologica Belgica 2/2021

15.04.2019 | Original article

Effects of resveratrol in the signaling of neuropathic pain involving P2X3 in the dorsal root ganglion of rats

verfasst von: Jinhui Guo, Chaowei Wang, Xiaolu Niu, Fang Zhou, Huiling Li, Weifang Gao

Erschienen in: Acta Neurologica Belgica | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Neuropathic pain is a major public health problem because it has a considerable impact on life quality of patients. Neuropathic pain caused by a lesion or disease of the somatosensory nervous system, which causes unpleasant and abnormal sensation (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in response to a stimulus that does not normally provoke pain (allodynia). P2X receptors from dorsal root ganglion (DRG) play a crucial role in facilitating pain transmission at peripheral and spinal sites. Resveratrol (Res) has neuroprotective effects and improves the pathological and behavioral outcomes of various types of nerve injury. The present study examined the effects of Res on neuropathic pain. Neuropathic pain animal model was created by partial sciatic nerve ligation (pSNL) surgery. We found that consecutive intraperitoneal administration of Res for 21 days reduced the mechanical and thermal nociceptive responses induced by pSNL in a dose-dependent manner. Moreover, Res administration reversed P2X3 expression and phosphorylation of ERK in DRG neurons after peripheral nerve injury. Our results suggested that Res may ameliorate neuropathic pain by suppressing P2X3 up-regulation and ERK phosphorylation in DRG of neuropathic pain rats. Therefore, we concluded that Res has a significant analgesic effect on alleviating neuropathic pain, and thus may serve as a therapeutic approach for neuropathic pain.
Literatur
4.
Zurück zum Zitat Burnstock G (2009) Purinergic receptors and pain. Curr Pharm Des 15(15):1717–1735CrossRef Burnstock G (2009) Purinergic receptors and pain. Curr Pharm Des 15(15):1717–1735CrossRef
25.
Zurück zum Zitat Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, Markman JD, Oaklander AL, Polydefkis MJ, Raja SN, Robinson JP, Woolf CJ, Ziegler D, Ashburn MA, Burke LB, Cowan P, George SZ, Goli V, Graff OX, Iyengar S, Jay GW, Katz J, Kehlet H, Kitt RA, Kopecky EA, Malamut R, McDermott MP, Palmer P, Rappaport BA, Rauschkolb C, Steigerwald I, Tobias J, Walco GA (2015) Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 156(7):1184–1197. https://doi.org/10.1097/j.pain.0000000000000191CrossRefPubMedPubMedCentral Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, Markman JD, Oaklander AL, Polydefkis MJ, Raja SN, Robinson JP, Woolf CJ, Ziegler D, Ashburn MA, Burke LB, Cowan P, George SZ, Goli V, Graff OX, Iyengar S, Jay GW, Katz J, Kehlet H, Kitt RA, Kopecky EA, Malamut R, McDermott MP, Palmer P, Rappaport BA, Rauschkolb C, Steigerwald I, Tobias J, Walco GA (2015) Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain 156(7):1184–1197. https://​doi.​org/​10.​1097/​j.​pain.​0000000000000191​CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3 Suppl):S3–S14. https://doi.org/10.4065/mcp.2009.0649CrossRef Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85(3 Suppl):S3–S14. https://​doi.​org/​10.​4065/​mcp.​2009.​0649CrossRef
28.
Zurück zum Zitat Ginnetti AT, Paone DV, Stauffer SR, Potteiger CM, Shaw AW, Deng J, Mulhearn JJ, Nguyen DN, Segerdell C, Anquandah J, Calamari A, Cheng G, Leitl MD, Liang A, Moore E, Panigel J, Urban M, Wang J, Fillgrove K, Tang C, Cook S, Kane S, Salvatore CA, Graham SL, Burgey CS (2018) Identification of second-generation P2X3 antagonists for treatment of pain. Bioorg Med Chem Lett 28(8):1392–1396. https://doi.org/10.1016/j.bmcl.2018.02.039CrossRefPubMed Ginnetti AT, Paone DV, Stauffer SR, Potteiger CM, Shaw AW, Deng J, Mulhearn JJ, Nguyen DN, Segerdell C, Anquandah J, Calamari A, Cheng G, Leitl MD, Liang A, Moore E, Panigel J, Urban M, Wang J, Fillgrove K, Tang C, Cook S, Kane S, Salvatore CA, Graham SL, Burgey CS (2018) Identification of second-generation P2X3 antagonists for treatment of pain. Bioorg Med Chem Lett 28(8):1392–1396. https://​doi.​org/​10.​1016/​j.​bmcl.​2018.​02.​039CrossRefPubMed
Metadaten
Titel
Effects of resveratrol in the signaling of neuropathic pain involving P2X3 in the dorsal root ganglion of rats
verfasst von
Jinhui Guo
Chaowei Wang
Xiaolu Niu
Fang Zhou
Huiling Li
Weifang Gao
Publikationsdatum
15.04.2019
Verlag
Springer International Publishing
Erschienen in
Acta Neurologica Belgica / Ausgabe 2/2021
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-019-01126-2

Weitere Artikel der Ausgabe 2/2021

Acta Neurologica Belgica 2/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.